Brokerages predict that Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Rating) will report earnings per share (EPS) of ($0.09) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Aileron Therapeutics’ earnings. Aileron Therapeutics reported earnings of ($0.06) per share in the same quarter last year, which indicates a negative year-over-year […]
Aileron Therapeutics (NASDAQ:ALRN – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. […]
Brokerages forecast that Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Rating) will report earnings of ($0.09) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Aileron Therapeutics’ earnings. Aileron Therapeutics posted earnings per share of ($0.06) in the same quarter last year, which suggests a negative year over […]
Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Rating) saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 153,600 shares, a drop of 17.0% from the April 15th total of 185,100 shares. Based on an average daily trading volume, of 360,700 shares, the days-to-cover ratio […]
Zacks Investment Research downgraded shares of Aileron Therapeutics (NASDAQ:ALRN – Get Rating) from a buy rating to a hold rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in […]